Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Well-Differentiated Neuroendocrine Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861
What this trial is testing

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Who this might be right for
GEP-NET
National Health Research Institutes, Taiwan 52
Testing effectiveness (Phase 2)Study completedNCT03278405
What this trial is testing

Avelumab in G3 NEC

Who this might be right for
Neuroendocrine Carcinoma
Sunnybrook Health Sciences Centre 10
Large-scale testing (Phase 3)Looking for participantsNCT06855095
What this trial is testing

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2+1 more
The Netherlands Cancer Institute 39
Not applicableStudy completedNCT03176485
What this trial is testing

Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

Who this might be right for
Metastatic CancerMelanomaColon Cancer+6 more
University of Arizona 45
Testing effectiveness (Phase 2)UnknownNCT04525638
What this trial is testing

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumours (NET)Neuroendocrine Carcinomas (NEC)
Fundación de investigación HM 30
Early research (Phase 1)Looking for participantsNCT07080242
What this trial is testing

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Who this might be right for
Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic Neuroendocrine Prostate Cancer+8 more
SystImmune Inc. 120
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Not applicableActive Not RecruitingNCT04970134
What this trial is testing

Spanish Study for Molecular Characterization of Thyroid Carcinoma

Who this might be right for
Differentiated Thyroid CarcinomaMedullary Thyroid Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello 150
Testing effectiveness (Phase 2)Study completedNCT00118248
What this trial is testing

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

Who this might be right for
Recurrent Thyroid CancerStage IV Follicular Thyroid CancerStage IV Papillary Thyroid Cancer+1 more
National Cancer Institute (NCI) 41
Early research (Phase 1)Looking for participantsNCT07165132
What this trial is testing

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+6 more
RayzeBio, Inc. 104
Testing effectiveness (Phase 2)Study completedNCT00654238
What this trial is testing

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Who this might be right for
Metastatic Differentiated Thyroid CancerMetastatic Poorly Differentiated Thyroid CancerMetastatic Anaplastic Thyroid Cancer+1 more
University of Pennsylvania 59
Testing effectiveness (Phase 2)Study completedNCT02806648
What this trial is testing

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

Who this might be right for
Pancreatic Neuroendocrine Cancer
Grupo Espanol de Tumores Neuroendocrinos 21
Large-scale testing (Phase 3)Enrolling By InvitationNCT07620574
What this trial is testing

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Who this might be right for
CancerRenal Cell Carcinoma (RCC)Pancreatic Neuroendocrine Tumors (pNET)+6 more
Exelixis 5,000
Testing effectiveness (Phase 2)Looking for participantsNCT05746208
What this trial is testing

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site
University of California, San Francisco 29
Testing effectiveness (Phase 2)Study completedNCT00519896
What this trial is testing

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Who this might be right for
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid Cancer+5 more
University of Washington 35
Large-scale testing (Phase 3)WithdrawnNCT04065165
What this trial is testing

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

Who this might be right for
Small Intestinal NETCarcinoid Heart Disease
European Organisation for Research and Treatment of Cancer - EORTC
Not applicableUnknownNCT06400654
What this trial is testing

PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC

Who this might be right for
Neuroendocrine Carcinoma
European Institute of Oncology 100
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT04759911
What this trial is testing

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Who this might be right for
Malignant Thyroid Gland NeoplasmPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Carcinoma+4 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Next Page
116
40